Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer Care
Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer Care
批准号:
10526667
负责人:
Michael Stuart Leapman
金额:
$12.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-01 至 2024-02-29
关键词:
AddressAdoptionAffectClinicalClinical ManagementClinical TrialsControlled StudyDataData SetDecision MakingDevelopmentDiagnosisDiseaseDisease ManagementGenomicsGoalsHealth SciencesHigh PrevalenceImageIndolentInterviewKnowledgeLearningMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMentored Research Scientist Development AwardMethodsMonitorNatureOutcomePatient CarePatientsPhasePhysiciansPositioning AttributeProstateQualitative ResearchResearchResearch PersonnelRiskRisk AssessmentShapesSurgeonTechnologyTechnology AssessmentTestingTraining ProgramsUncertaintyUniversitiesWorkcancer carecancer riskcomparativecostimplementation scienceimprovedmennew technologyovertreatmentpatient orientedpractice settingprostate cancer riskside effectskillstoolunnecessary treatment
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
New, expensive risk assessment technologies are rapidly being integrated into the care of patients with
prostate cancer. Advanced imaging (prostate MRI) and genomic tests have been developed and are now
deployed to overcome a central challenge in the management of the disease: a remarkably high prevalence,
yet comparatively low lethality. For decades, uncertainty regarding the true nature of a patient's prostate
cancer has led to the unnecessary treatment of indolent (`low-risk') disease in millions of men resulting in
lasting side-effects for many. By improving the ability to distinguish low-risk from aggressive cancers, it is
believed that more accurate tools will allow many patients to safely observe low-risk cancers with careful
monitoring (active surveillance). Although these two ascendant technologies have been evaluated in controlled
studies, no real-world evidence is available to understand their impact. Specifically, it is not known which
patients are receiving testing, whether use of these technologies reduces unnecessary treatment, or how
patients and doctors perceive of their benefit. To address these knowledge gaps, we aim to comprehensively
understand how prostate MRI and genomic testing impact the management of prostate cancer. We will
accomplish this goal through two complementary phases aimed at: (1) defining how adoption of prostate MRI
and/or genomic testing has affected clinical management, and (2) understanding how patients and physicians
perceive of these tools during decision-making. We hypothesize that whether or not prostate MRI and/or
genomic testing are performed is dependent on the doctor that they see, but that testing is associated with
lower rates of treatment. We will use large national datasets of men with prostate cancer and examine the
adoption of prostate MRI and/or genomic testing, and whether the use of these technologies is associated with
increased use of observation versus treatment. To learn how these tools are used in decision-making for low-
risk prostate cancer, we will conduct in-depth interviews of both patients with prostate cancer and doctors who
diagnose and treat the disease. The results from this research will shape efforts to improve how these tools are
used in the management of men with prostate cancer. Candidate: this proposal supports the professional
development of the candidate as an independent, patient-oriented surgeon-investigator focusing on improving
prostate cancer care. This application is centered around a rigorous training program including coursework that
leverages the candidate's background as a prostate cancer surgeon and clinical outcomes researcher whose
prior work has focused on risk assessment technologies and active surveillance of low-risk prostate cancer.
The applicant will build upon his expertise by earning a Masters in Health Science from Yale University, and
develop a skill set in qualitative research and implementation science. The completion of this mentored training
award will position the candidate to develop and test a framework for refining the use of new technologies for
patients with prostate cancer, potentially reducing over-treatment and cost.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1001/jamanetworkopen.2021.28646
发表时间:
2021-10-01
期刊:
JAMA network open
影响因子:
13.8
作者:
[Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP]
通讯作者:
Gross CP
DOI:
10.1007/s00261-020-02496-5
发表时间:
2020-12
期刊:
Abdominal radiology (New York)
影响因子:
--
作者:
[Rajwa P, Syed J, Leapman MS]
通讯作者:
Leapman MS
National trends in the management of patients with positive surgical margins at radical prostatectomy.
根治性前列腺切除术中手术切缘阳性患者管理的全国趋势。
DOI:
10.1007/s00345-020-03298-6
发表时间:
2021
期刊:
World journal of urology
影响因子:
3.4
作者:
[Ghabili,Kamyar, Park,HenryS, Yu,JamesB, Sprenkle,PrestonC, Kim,SimonP, Nguyen,KevinA, Ma,Xiaomei, Gross,CaryP, Leapman,MichaelS]
通讯作者:
Leapman,MichaelS
DOI:
10.1002/cam4.3482
发表时间:
2020-12
期刊:
Cancer medicine
影响因子:
4
作者:
[Kaps B, Leapman M, An Y]
通讯作者:
An Y
DOI:
10.1097/upj.0000000000000109
发表时间:
2020-07
期刊:
Urology practice
影响因子:
0.8
作者:
[Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, Park H, Yu JB, Gross CP, Davidoff AJ, Leapman MS]
通讯作者:
Leapman MS
Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imaging
-
批准号:10712074
-
项目类别:
-
资助金额:$66.04万
-
财政年份:2023
-
负责人:Michael Stuart Leapman
-
依托单位:
Understanding the Adoption and Impact of New Risk Assessment Technologies in Prostate Cancer Care
-
批准号:10352214
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2019
-
负责人:Michael Stuart Leapman
-
依托单位:
海外基金